Fulcrum announces Phase 3 trial of losmapimod
Posted on March 3rd, 20223/3/22
From Fulcrum Therapeutics’ press release Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022 Potential first-to-market therapy for […]
Filed under: FSHD Research, General
